Amarin sells heart pill Vascepa's rights in Europe to Recordati amid restructuring bid
Amarin has forged a licensing deal with Italian pharma Recordati to commercialize its fish oil-derived heart pill Vascepa. Recordati will pay Amarin $25 million upfront to market the product to 59 European countries.
Amarin has forged a licensing deal with Italian pharma Recordati to commercialize its fish oil-derived heart pill Vascepa. Recordati will pay Amarin $25 million upfront to market the product to 59 European countries.
